Cargando…
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair deficiency setting, while safety and efficacy of combining dual-checkpoint inhibitor immunotherapy with chemotherapy remains uncertain. Here, we p...
Autores principales: | Renouf, Daniel J., Loree, Jonathan M., Knox, Jennifer J., Topham, James T., Kavan, Petr, Jonker, Derek, Welch, Stephen, Couture, Felix, Lemay, Frederic, Tehfe, Mustapha, Harb, Mohammed, Aucoin, Nathalie, Ko, Yoo-Joung, Tang, Patricia A., Ramjeesingh, Ravi, Meyers, Brandon M., Kim, Christina A., Du, Pan, Jia, Shidong, Schaeffer, David F., Gill, Sharlene, Tu, Dongsheng, O’Callaghan, Chris J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418247/ https://www.ncbi.nlm.nih.gov/pubmed/36028483 http://dx.doi.org/10.1038/s41467-022-32591-8 |
Ejemplares similares
-
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022) -
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020) -
An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab
por: Diaz-Rodriguez, Porfirio E, et al.
Publicado: (2023) -
Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023) -
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)